Will Chemours TT segment Adjusted EBITDA margin print below 5% in any quarter of 2026?
Current Prediction
Why This Question Matters
TT segment is already at trough (6% margin FY2025, 52% EBITDA decline, 30% Asia revenue fall). A sustained print below 5% in any 2026 quarter would signal structural impairment and shift CAPITAL_DEPLOYMENT toward divestiture. Four regions of antidumping duties and 1.1M tons of capacity rationalization have not lifted margins, which is itself a negative signal. Tests whether the TT cycle has bottomed or continues to deteriorate.
Prediction Distribution
Individual Predictions(9 runs)
FY2025 TT margin was 6% (trough). Quarterly volatility is typically 3-5 percentage points. Q1 is seasonally weakest; probability Q1 2026 prints below 5% on seasonality alone is ~35-45%. 'Any quarter' criterion gives 4 shots, but quarterly margins are autocorrelated. Joint probability across 4 correlated quarters is materially higher than single-quarter but less than 4x independent. Management 'stable market' guide + Asia -30% + 1.1M ton rationalization that hasn't lifted margins all argue for trough-persistence. 0.40 captures elevated probability with acknowledgment that antidumping duty bite could lift H2 margins.
The key signal is 1.1M tons of rationalization without margin recovery — this is bearish for cyclical bottoming hypothesis. However, management's specific 'stable market' guide (not 'weakening') is revealed-preference against a further leg down. Q1 2026 10-Q timing: the analysis date is 2026-04-22 so Q1 data may be imminent or already flowing. Absence of pre-announce warning suggests Q1 is not dramatically below 6%. Probability of Q1 sub-5% on seasonality ~30-40%, Q2-Q4 each ~25-30% given stable guide. Joint accounting for autocorrelation ~0.36.
Quarterly margin volatility around a 6% trough gives meaningful probability that at least one quarter crosses below 5%. Q1 seasonality is the highest-probability shot (35-45%). Q4 could also be weak if inventory correction returns. Commodity chemicals at trough tend to spend more time below trailing average during cycle bottom. Asia -30% and no volume growth guide reinforce downside. Antidumping duty enforcement timing is uncertain — may not hit margins in 2026. 0.42 reflects committee's CONDITIONAL revenue durability and MIXED capital deployment read.
Math: P(Q1 sub-5%) ~0.35, P(any Q2-Q4 sub-5% conditional on stable market) ~0.20 per quarter. If we assume modest correlation between quarters, P(any 2026 Q sub-5%) ~0.35 + 0.20 + 0.15 + 0.10 (marginal with correlation) = 0.40ish, adjusted to 0.37 for the stable-market guide. Committee's CONDITIONAL classification supports elevated but not high probability.
FY2025 at 6% with 2H-weighted recovery dynamics and antidumping duty effects (building through 2026) could produce 2026 FY margin ~6-8%. Crossing below 5% in any individual quarter requires a specific weak quarter (Q1 seasonality). 0.35 reflects seasonality-driven Q1 probability minus duty-driven recovery lift.
The 'any quarter' framing means a single weak quarter triggers YES. Quarterly volatility at trough is meaningful. 1.1M tons of capacity rationalization without recovery is a strong bearish signal — supports continued trough. Balanced probability 0.40 captures genuine uncertainty about whether TT is at floor or leg-down.
6% FY trough with 3-5pp quarterly volatility and Q1 seasonal weakness gives ~35-45% probability of a sub-5% quarter. 0.38 captures middle.
4 quarterly shots against a 6% FY trough with seasonality; base rate ~0.40. Stable-market guide pulls down slightly; antidumping uncertainty offsets. Settle 0.40.
Base 35-40% reflecting seasonal Q1 + 4 correlated shots + stable guide. Settle 0.37.
Resolution Criteria
Resolves YES if any of Q1 2026, Q2 2026, Q3 2026, or Q4 2026 quarterly disclosures (10-Q filings through Q3 2026; Q4 2026 preliminary results via earnings release) show TT segment Adjusted EBITDA margin below 5.0% (calculated as Adjusted EBITDA / segment net sales). Resolves NO if all four quarters of 2026 print TT Adjusted EBITDA margin at or above 5.0%, or if segment reporting is reorganized/discontinued without a clean TT disclosure in any quarter of 2026.
Resolution Source
Chemours 10-Q filings Q1-Q3 2026, Q4 2026 earnings release or 10-K
Source Trigger
Titanium Technologies (TT) EBITDA Margin — Sustained below 5% signals structural impairment; above 12% implies recovery
Full multi-lens equity analysis